Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics DifferentlyNazar Farid, Daniel E. Salazar, Christopher D. Payne et al.|Clinical Pharmacology & Therapeutics|2007Cited by 323
Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose ClopidogrelChristopher D. Payne, Kenneth J. Winters, Ying Grace Li et al.|Journal of Cardiovascular Pharmacology|2007Cited by 167
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administrationChristopher D. Payne, Joseph A. Jakubowski, Ying G. Li et al.|Thrombosis and Haemostasis|2008Cited by 120
Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy SubjectsNagy A. Farid, Kenneth J. Winters, John T. Brandt et al.|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2008Cited by 87
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometryChristopher D. Payne, Joseph A. Jakubowski, Ying G. Li et al.|Thrombosis and Haemostasis|2007Cited by 79